the germ line genetic screening necessary for men with prostate cancer metastatic -
Men with metastatic prostate should be considered for genetic testing germ repair genes DNA, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering cancer Center (MSK), Fred Hutchinson cancer Research Center, cancer Institute Dana-Farber, University of Washington School of Medicine, University of Michigan, and the research Institute of the Royal Marsden Cancer Hospital.
in a study published online in the New England Journal of Medicine July 6, researchers have shown an association between cancer and mutations advanced prostate in repair genes DNA and found that these mutations are much more often in advance as opposed to localized disease (11.8 percent against 4.6 percent).
people have shown for germ cell cancer predisposing mutations may serve as sentinels that identify high risk families. For example, those who had a DNA repair defect, a very high proportion had a first degree relative with cancers other than prostate cancer compared to the group who did not repair mutations DNA. The identification of a mutation in the DNA repair gene germline provides essential information for parents, and for the patient, causing a cascade of tips to identify cancer susceptibility and deploy risk reduction strategies in family members. Thinking beyond the present and looking for opportunities to prevent the next generation of cancer, this work will create a major paradigm shift.
"With the exception of certain cancer syndromes in children, prostate cancer is the most heritable of human malignancies," said Michael F. Walsh, MD, co-principal author of the study and a geneticist and pediatric oncologist at MSK. "Historically, the main advantage to identify the mutations that cause cancer is prevention and early detection in families. Now we can use inherited genomic information to target the treatment with specific therapies proven effective in those with specific genomic subsets of prostate cancer. "
MSK researchers used powerful new resource Niehaus MSK Center for Inherited cancer genomics to explore genomic and clinical links between mutations in the DNA repair gene and cancer advanced prostate.
"These results are interesting for two reasons," explained Kenneth Offit, MD, MPH, chief of the clinical genetics Service, head of Niehaus Center, and author co-main of the study. "First, these findings could change clinical practice because we now show that the tests of these DNA repair genes should be offered to all men with advanced prostate cancer. The second important conclusion is that we see clusters of cancers other than prostate, breast, ovarian, and pancreatic cancer in families that are not expected and that will boost research. "
prospective studies are needed to determine whether mutations in the DNA repair gene are predictive of clinical outcomes.
EmoticonEmoticon